CMPX vs CNTX
CMPX: Compass Therapeutics is a clinical-stage oncology company developing a pipeline of bispecific and agonistic antibodies designed to treat solid tumors by targeting angiogenesis and immune system pathways. CNTX: Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer cells.
Side-by-side fundamentals
| Metric | CMPX | CNTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.08 | $0.622 | |
| Market cap as of 2026-07-31 | $349M | $57M | |
| PEG as of 2026-07-31 | -1.73 | -0.06 | CMPX lower |
| Net margin as of 2026-07-31 | -5808.8% | n/a | |
| Operating margin as of 2026-07-31 | -6661.8% | n/a | |
| ROE as of 2026-07-31 | -29.9% | -60.0% | CMPX higher |
| ROA as of 2026-07-31 | -26.4% | -54.8% | CMPX higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-31 | 0.86 | 1.75 | |
| 1-year return as of 2026-07-27 close | -34.6% | -26.0% | CNTX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.